首页> 外文期刊>BMC Infectious Diseases >Spot specimen testing with GeneXpert MTB/RIF results compared to morning specimen in a programmatic setting in Cotonou, Benin
【24h】

Spot specimen testing with GeneXpert MTB/RIF results compared to morning specimen in a programmatic setting in Cotonou, Benin

机译:与Genexpert MTB / RIF结果的现象测试与Cotonou,Benin的Procinematic设置中的早晨标本相比

获取原文
       

摘要

The diagnosis of tuberculosis (TB) using smear microscopy has been based on testing two specimens: one spot and one early morning sputa. Recently, the World Health Organization (WHO) has recommended to replace, whenever possible, microscopy with GeneXpert? MTB/RIF performed on a single specimen. However, as the bacterial load is higher in early morning specimens than in spot specimens, one could expect lower sensitivity of GeneXpert? MTB/RIF performed only on spot specimens. In this study, we compared results of GeneXpert? MTB/RIF on spot specimens versus early morning specimens, under programmatic conditions in Cotonou, Benin. From June to September 2018, all sputa received from presumptive TB patients at the Supranational Reference Laboratory for Tuberculosis of Cotonou were included in the study. From each patient, two specimens were collected (one spot and one early morning) and GeneXpert? MTB/RIF was performed on both specimens. In total, 886 participants were included in the study, of whom 737 provided both sputa and 149 (16.8%) gave only the spot specimen. For the 737 participants who provided both sputa, GeneXpert? MTB/RIF was positive for both specimens in 152 participants; for three participants GeneXpert? MTB/RIF was positive on spot specimen but negative on morning specimen while for another three, the test was positive on morning specimen but negative on spot specimen. The overall percentage of agreement was excellent (99.2%) with a positive and negative percent agreement greater than 98%. For TB diagnosis under programmatic conditions in Cotonou, GeneXpert? MTB/RIF in spot specimens gave similar results with the test in morning specimens. Performing GeneXpert? MTB/RIF in both specimens did not significantly increase the number of cases detected. To avoid losing patients from the diagnostic cascade, it is preferable to test sputa produced at the time of the first visit at the health center.
机译:使用涂片显微镜的结核病(TB)的诊断基于试验两种标本:一个点和一个清晨的烟花。最近,世界卫生组织(世卫组织)建议尽可能替换与Genexpert的显微镜检查? MTB / RIF在单个样本上进行。然而,由于清晨标本的细菌载荷高于点标本,因此可以期望Genexpert的敏感性较低? MTB / RIF仅在点标本上进行。在这项研究中,我们比较了Genexpert的结果? MTB / RIF在现场标本与清晨标本,在贝宁的Cotonou的程序性条件下。从6月到2018年9月,从推测TB患者收到的所有Sputa都在Cotonou的结核病的Supronational参考实验室中被列入该研究。从每位患者,收集两种标本(一个点和一个清晨)和Genexpert? MTB / RIF在两个样本上进行。总共包括886名参与者,其中737名提供了737个,其中斯普拉和149名(16.8%)只给出了现象。对于提供斯普卢塔的737名参与者,Genexpert?在152名参与者中,MTB / RIF对于两个标本为阳性;三位参与者Genexpert? MTB / RIF在现象上是阳性的,但在早晨标本上是阴性的,而另外三个,测试在早晨标本上是阳性的,但在斑点标本上是负面的。协议的总体百分比为优秀(99.2%),持股和负数百分比大于98%。对于Cotonou,Genexpert的编程条件下的TB诊断?在斑点标本中的MTB / RIF在早晨标本中测试了类似的结果。执行Genexpert?两个标本中的MTB / RIF没有显着增加检测到的病例数。为避免从诊断级联失去患者,优选在第一次访问健康中心时测试斯普拉。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号